XstalBio Press Releases
|
Improved Anthrax Vaccine 12 Jun 06 - 09:00 Improved anthrax vaccine: XstalBio collaborates with Avecia for further development and improved stability XstalBio is collaborating with Avecia Biotechnology on a $3.9 m grant from the US Government for further development of ThraxineTM, its recombinant protective antigen (rPA) anthrax vaccine. The aim of this collaboration is to develop an imp... View Detail Licence Agreement with Boehringer Ingelheim Pharma16 May 06 - 09:00 XstalBio Ltd signs a licence agreement with Boehringer Ingelheim Pharma GmbH &Co. KG for its protein formulation and drug delivery technology. XstalBio is a Glasgow-based company specialising in the formulation of protein-based drugs into particles that can be engineered for advanced drug delivery applications. XstalBio has signed a licence agreement with Boehringer Ingelheim Pharm... View Detail
|
|
|
|
|
|
|
|
|
|
|
